Medistim have received confirmation from Canada Health that the company’s new product VeriQ C is cleared for sale in Canada.Read more
Findings substantiate the VeriQ system’s ability to improve outcomes for coronary artery bypass surgery and contain costs.
MINNEAPOLIS, MINN. (Nov. 17, 2011) – A longtime leader in setting world-class standards for health care is recognizing the effectiveness of a life-saving technology produced by an international medtech company that has a vibrant presence in the United States.Read more
Medistim has signed contracts with three hospitals in the US and achieved its first revenues from the company’s new product VeriQC.
All three hospitals have entered into a lease agreement where they pay per usage. A procedure with VeriQC is priced at about twice the level of a procedure performed using the traditional equipment VeriQ™. The company expects that existing and new customers gradually will convert to VeriQC.Read more
A new transit time flow measurement (TTFM) probe line specifically designed for vascular surgery is being launched at the annual conference of the European Society for Vascular Surgery (ESVS).Read more
MediStim ASA (OSE: MEDI), a Norwegian Medtech company that develops and commercializes medical equipment for use within cardiac and vascular surgery, as well as other surgical fields, announces that the company has entered into a license agreement with Freebit AS.Read more